Clinical-stage Opportunity Avelas is a clinical-stage biotech focusing on real-time cancer detection during surgery with the AVB-620 fluorescent imaging agent. This presents a sales opportunity to engage early adopters in surgical oncology, particularly institutions pursuing intraoperative imaging enhancements and precision surgery.

Breast Cancer Anchor Prospective data suggest pegloprastide identifies cancer in up to 75% of positive-margin breast-conserving surgeries, highlighting a strong initial market in breast cancer workflows and a potential expansion path into additional breast procedures and centers of excellence.

Expansion Across Cancers Beyond breast cancer, Avelas aims to adapt pegloprastide for ovarian, colorectal, head and neck, melanoma, and sarcoma surgeries. This indicates a broad, multi-tumor expansion plan that can drive cross-sell opportunities across varied surgical oncology programs.

Strategic Partnerships With a small team and early-stage revenue, Avelas would benefit from collaborations with leading surgical device manufacturers, imaging system suppliers, and hospital networks to co-market and integrate AVB-620 with fluorescence camera platforms and workflow integrations.

Regulatory/Quality Focus Key hires in Regulatory and Quality and board expansion in 2021 suggest a priority on regulatory readiness and quality systems. This signals potential conversations around getting multi-center approvals, reimbursement strategies, and alignment with hospital procurement standards as a sales path.